Phaseline

Companies › Biossil

Biossil: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 3 Phase 2; Neurology, Hematology, Respiratory; next expected readout Oct 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Senicapoc (SIL-8301)
Intermediate conductance calcium-activated potassium channel protein 4 blocker
Ion channelsPhase 2Sickle Cell Disease; Mild Cognitive Impairment; Pulmonary Fibrosis, Interstitial Lung DiseaseOct 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04804241Senicapoc (SIL-8301)Phase 2Mild Cognitive ImpairmentNeurologyDec 2027
NCT06714123Senicapoc (SIL-8301)Phase 2Pulmonary Fibrosis, Interstitial Lung DiseaseRespiratoryDec 2028
NCT07282210Senicapoc (SIL-8301)Phase 2Sickle Cell DiseaseHematologyOct 2029

Targets

Ion channels (1)

Companies with the same targets

Xenon Pharmaceuticals Praxis Precision Medicines HB BioTech Encoded Therapeutics Biohaven Therapeutics TLC Biopharmaceuticals Shenzhen Ausa Pharmed Grace Therapeutics LXO Ireland Jiangsu HengRui Medicine

Companies built like this

Actio Biosciences Halia Therapeutics Nuvig Therapeutics Aspeya Shenzhen Ausa Pharmed

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.